Pollen Allergy Immunotherapy: Evidence Mapped by Pollen Type

Yes, allergy shots (SCIT) are an established treatment for pollen allergies, with the strongest evidence for grass pollen. Frew et al. (JACI 2006) — the largest single grass SCIT randomized controlled trial (n=410) — demonstrated a 29% overall symptom score reduction and a 32% medication reduction versus placebo, rising to 32% and 41% during peak pollen season. Durham et al. (NEJM 1999) established that this benefit persists at least 3 years after stopping a 3-4 year treatment course, demonstrating genuine disease modification. Evidence for tree pollen SCIT is moderate, with roughly 40% symptom reduction in high-quality birch trials. Ragweed SCIT is effective for nasal symptoms but had limited asthma benefit in the Creticos 1996 NEJM trial. A board-certified allergist can determine whether your specific pollen sensitization profile is well served by available SCIT or SLIT options.

The best immunotherapy for pollen allergy depends on which pollen type drives your symptoms. For grass pollen, both SCIT shots and FDA-approved sublingual tablets (Grastek, Oralair) offer strong, equivalent evidence per the Nelson 2015 network meta-analysis — so patient preference for convenience or needle avoidance can guide the choice. For ragweed, the FDA-approved Ragwitek sublingual tablet and conventional SCIT are both options for rhinitis. For most tree pollens including birch, SCIT is the primary evidence-supported choice; no FDA-approved sublingual tablet is available in the US for birch or other tree species. For polysensitized patients reacting to multiple pollen types simultaneously, a multi-allergen SCIT mix or off-label multi-allergen sublingual drops may be the most practical approach.

No FDA-approved sublingual tablet exists for birch or most other tree pollen allergies in the US as of 2025. The three FDA-approved sublingual tablets for pollen — Grastek (timothy grass), Oralair (five-grass mix), and Ragwitek (short ragweed) — do not include birch, cedar, oak, or other tree species. A Japanese cedar sublingual tablet (Cedarcure) is approved in Japan but not in the US. The Worm 2019 phase III trial of a birch SLIT tablet missed its primary endpoint in the full analysis, though it succeeded in a high-pollen-exposure subgroup. This means that tree pollen patients in the US are largely limited to conventional SCIT or off-label sublingual drops for immunotherapy, with SCIT being the more evidence-supported option.

Most pollen-allergic patients begin noticing symptom improvement within the first allergy season after starting immunotherapy, typically 3-6 months into treatment. For sublingual tablets, the label recommends starting 4 months (Oralair) or 12 weeks (Grastek, Ragwitek) before the pollen season to achieve the pre-seasonal dosing benefit documented in pivotal trials. For SCIT, symptom improvement generally tracks the progression through the buildup phase toward maintenance dosing. The critical milestone for lasting benefit — relief that persists after you stop treatment — requires at least 3 years of therapy. Scadding et al. (JAMA 2017) demonstrated that 2-year courses of either SCIT or SLIT were insufficient to produce durable post-treatment benefit. Consistent treatment completion is more predictive of long-term outcomes than the modality chosen.

Yes, but the evidence picture is more complex for polysensitized patients. Multi-allergen SCIT mixes are the standard US approach for patients sensitive to multiple pollen types, and large real-world observational data suggest clinical benefit comparable to monosensitized patients. However, Nelson's 2009 review identified that for mixes of more than two unrelated allergens, evidence quality falls — 3 of 5 multi-allergen mix studies showed efficacy and 2 showed none, likely due to subtherapeutic per-component dosing. European guidelines often favor treating the single dominant allergen even in polysensitized patients. For SLIT tablets, polysensitized patients face a practical limitation: each FDA-approved tablet covers only one allergen, requiring separate prescriptions for each pollen type. Off-label multi-allergen sublingual drop formulations can combine multiple pollen allergens, but these lack the standardized trial evidence of individual tablets.

For grass pollen, multiple head-to-head analyses have found no statistically significant efficacy difference between SCIT injections and FDA-approved sublingual tablets. The Nelson 2015 network meta-analysis found a symptom SMD difference of only 0.01 between the two modalities for grass — essentially equivalent. The meaningful differences are in safety, convenience, and cost. Sublingual tablets have zero confirmed fatalities worldwide versus roughly 1 per 2.5 million SCIT injections historically, and are approved for at-home dosing after a supervised first dose. SCIT requires weekly clinic visits for months, then monthly appointments for years, consuming roughly 100+ hours of patient time over a 3-year course versus about 27 hours for sublingual treatment. SCIT, however, retains an advantage for polysensitized patients needing multi-allergen mixes, since each sublingual tablet covers only one allergen species.

Allergy shots for pollen allergies are typically administered year-round rather than only during pollen season. The AAAAI/ACAAI Joint Task Force Practice Parameter recommends ongoing maintenance therapy for 3-5 years regardless of season, as stopping during off-season periods would disrupt the immune tolerance being built. Some allergists temporarily hold or reduce the dose during a patient's peak pollen season as a precaution — peak season administration was noted in 46% of near-fatal SCIT reactions in AAAAI surveillance data — though this practice is not uniformly supported by controlled trials. With at-home SCIT through Curex, that year-round maintenance is self-administered at home, and dose changes are supervised live over Zoom by the prescribing allergist, who sets the seasonal dosing strategy for your specific pollen sensitization profile.